Richtlijn CVRM feb2013 - KNMP

Wright 2002
Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure
lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from
the AASK trial. JAMA 2002; 288: 2421-2431.
Wright 2009 Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009 jul 8 (3)
CD001841.
Ye 2012
Ye Y, Zhao X, Zhai G, Guo L, Tian Z, Zhang S. Effect of High-Dose Statin Versus Low-Dose
Statin Plus Ezetimibe on Endothelial Function: A Meta-analysis of Randomized Trials. J
Cardiovasc Pharmacol Ther. 2012 Jun 18. [Epub ahead of print].
Yusuf 2000
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme
inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
Yusuf 2008 Yusuf S, Teo KK, Pogue J et al. The ONTARGET investigators. Telmisartan, Ramipril or both in
Patients at High Risk for Vascular Events. N Engl J Med 2008; 358: 1547-1559.
Zhao 2011 Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M et al. "Triple therapy" rather than
"triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in
patients receiving long-term oral anticoagulant treatment. Chest. 2011 Feb;139(2):260-70.
Zhou 2006 Zhou Z, Rahme E, Pilote E. Are statins created equal Evidence from randomized trials of
pravastatin, simvastatin, and atrovastatin for cardiovascular disease prevention. Am Heart J 2006;
151: 273-81.
CONCEPT
102